Financial Performance - The company's revenue for Q3 2022 reached ¥2,484,372,974.44, representing a 41.15% increase compared to the same period last year[3] - Net profit attributable to shareholders for Q3 2022 was ¥357,469,296.76, a 4.22% increase year-over-year[3] - The net profit after deducting non-recurring gains and losses for Q3 2022 was ¥328,157,282.62, up 2.08% from the previous year[3] - The company reported a 31.31% increase in total revenue for the first nine months of 2022, amounting to ¥7,642,317,470.16[8] - For the first three quarters of 2022, the company achieved a total revenue of 7.58 billion RMB, representing a year-on-year growth of 31.0%[15] - The net profit attributable to shareholders for the same period was 1.25 billion RMB, an increase of 13.3% year-on-year, while the adjusted net profit was 1.32 billion RMB, up 21.4%[15] - In Q3 2022, the company reported a revenue of 2.46 billion RMB, a 39.3% increase compared to the same quarter last year, with a net profit of 360 million RMB, growing 4.2% year-on-year[15] - Total operating revenue for Q3 2022 reached CNY 7,642,317,470.16, a significant increase from CNY 5,819,940,390.58 in Q3 2021, representing a growth of approximately 31.3%[23] - Net profit for Q3 2022 was CNY 1,266,801,259.01, compared to CNY 1,104,045,577.95 in the same period last year, marking an increase of about 14.7%[24] - Basic earnings per share for Q3 2022 were CNY 2.97, up from CNY 2.59 in Q3 2021, reflecting a growth of approximately 14.7%[25] Assets and Liabilities - The total assets as of September 30, 2022, amounted to ¥16,499,013,599.80, reflecting a 24.36% increase from the end of the previous year[3] - The company's total assets as of September 30, 2022, amounted to CNY 16.50 billion, an increase from CNY 13.27 billion at the beginning of the year[19] - Current assets totaled CNY 10.80 billion, compared to CNY 10.35 billion at the beginning of the year[19] - The total liabilities reached CNY 4.66 billion, up from CNY 2.58 billion at the beginning of the year[21] Cash Flow - The cash flow from operating activities for the year-to-date period reached ¥1,208,226,864.65, showing a significant increase of 180.75%[3] - Cash flow from operating activities for Q3 2022 was CNY 1,208,226,864.65, a substantial increase from CNY 430,363,319.55 in Q3 2021, indicating a growth of about 180.2%[27] - The company reported a net cash outflow from investment activities of CNY -2,542,732,087.90 in Q3 2022, contrasting with a net inflow of CNY 719,734,164.27 in Q3 2021[27] - The net cash flow from financing activities was 805,357,306.18 CNY, compared to a negative cash flow of 901,960,655.48 CNY in the previous period[28] - The company reported a net decrease in cash and cash equivalents of 486,349,865.30 CNY, contrasting with an increase of 246,269,923.06 CNY in the previous period[28] Investments and Acquisitions - The company completed the acquisition of three subsidiaries in 2022, contributing a combined revenue of ¥398,410,400 and a net profit of ¥35,384,700 during the reporting period[4] - Investment cash outflows reached approximately 6.89 billion RMB, a 60.84% increase year-on-year, primarily due to increased purchases of financial products[10] - The company made cash payments of approximately 1.60 billion RMB for acquisitions, marking a 100% increase as it expanded its business through mergers[10] Revenue Growth by Segment - The medical business segment generated 4.83 billion RMB in revenue for the first three quarters, a significant increase of 56.8% year-on-year, with three acquired companies contributing 400 million RMB[15] - The company's protective products saw a revenue increase of 68.1% year-on-year, while high-end wound dressing products surged by 323.0%[15] - The hospital channel revenue grew by 163.3% year-on-year, while the C-end channel (pharmacies + e-commerce) increased by 39.0%[15] Research and Development - Research and development expenses for the first nine months of 2022 totaled ¥374,437,954.15, a 37.85% increase year-over-year[8] Membership and Store Growth - As of the end of Q3 2022, the total number of members reached approximately 42 million, with a total of 339 stores (including 27 franchise stores), adding 34 new stores compared to the end of last year[17] Brand Engagement and Certification - The company launched a series of original content to enhance brand engagement, including the "She Changed" series featuring influential women[17] - The company announced that three classic products received SGS product carbon footprint certification during the "818 Member Season" event[17] Other Financial Metrics - The company reported a total operating cost of CNY 6,185,665,585.33 for Q3 2022, compared to CNY 4,705,361,091.03 in Q3 2021, which is an increase of about 31.5%[23] - The company’s interest income for Q3 2022 was CNY 90,273,306.67, compared to CNY 55,628,271.44 in Q3 2021, marking an increase of approximately 62.3%[23] - Total cash inflow from investment activities in Q3 2022 was CNY 6,815,077,669.22, compared to CNY 5,517,393,623.52 in Q3 2021, representing an increase of approximately 23.5%[27] Dividend and Profit Distribution - The company paid 409,802,625.20 CNY in dividends, interest, or profit distributions, down from 568,158,834.96 CNY previously[28] Audit Status - The company has not audited the third-quarter report[29]

Financial Performance - The company's operating revenue for the reporting period was ¥5,157,944,495.72, representing a 27.05% increase compared to ¥4,059,865,654.92 in the same period last year[14]. - Net profit attributable to shareholders was ¥892,823,503.14, up 17.32% from ¥761,038,730.24 year-on-year[14]. - The net cash flow from operating activities increased by 305.43%, reaching ¥801,150,899.38, compared to ¥197,604,865.77 in the previous year[14]. - Basic earnings per share rose to ¥2.1193, an increase of 18.77% from ¥1.7844 in the same period last year[14]. - The overall revenue for H1 2022 was CNY 5.11 billion, reflecting a 27.36% increase from CNY 4.01 billion in H1 2021[59]. - The total operating costs amounted to CNY 4,122,305,279.41, up from CNY 3,268,705,562.33, reflecting a year-over-year increase of about 26.1%[191]. - The net profit attributable to the parent company was ¥892,823,503.14, up from ¥761,038,730.24 in the previous year, indicating an increase of about 17.3%[193]. - The total profit for the first half of 2022 was ¥1,043,198,245.70, compared to ¥904,406,345.08 in the previous year, showing an increase of about 15.4%[192]. Acquisitions and Investments - The company completed acquisitions of 隆泰医疗 (55% stake for ¥7.3 billion), 湖南平安医械 (68.7% stake for ¥7.5 billion), and 桂林乳胶 (100% stake for ¥4.5 billion), enhancing its product line and market presence[65]. - The company invested a total of RMB 1,929.46 million to acquire 55% of Longtai Medical, 68.70% of Ping An Medical, and 100% of Guilin Latex, enhancing its position as one of the most comprehensive medical consumables companies in China[168]. - The total investment amount for the reporting period was CNY 4,609,168,278.88, representing a 61.43% increase compared to CNY 2,855,178,484.95 in the same period last year[99]. - The company plans to use raised funds for high-end wound dressing production line construction, marketing network development, R&D center establishment, and digital management system projects[125]. Market and Product Development - The company has expanded its product lines to include high-end wound dressings and infection prevention products, enhancing its market position in the medical consumables sector[23]. - The medical segment generated a revenue of 3.23 billion yuan, up 45.3% year-on-year, with epidemic prevention products increasing by 53.9% and high-end dressings by over 260%[55]. - The company has established a strong brand reputation in the medical consumables sector, recognized as a market leader and praised for its contributions during the pandemic, receiving accolades from the State Council and the Central Committee of the Communist Party of China[49]. - The company has developed high-end moist dressings for chronic wounds, including silicone foam dressings and hydrocolloid dressings, further expanding its product layout[46]. Research and Development - Research and development expenses increased by 25.66% to ¥238,644,498.62, reflecting the company's commitment to innovation[67]. - The company has developed core materials for masks and protective clothing, with several products already in the verification stage, including an antibacterial fiber dressing approved by the FDA[62]. - The company has established partnerships with various universities and research institutions to enhance its R&D capabilities, including the establishment of an innovation research institute with Wuhan Textile University[42]. Sales and Marketing - The company has a comprehensive sales network, covering over 14,000 retail pharmacies and more than 4,000 hospitals across 30 provinces in China[52]. - The company has integrated online and offline channels, achieving nearly 40 million users for the "Purcotton" brand, with over 19 million registered members on private domain platforms[53]. - The company achieved sales revenue of ¥545,164,917.16 through the Taobao platform, with a return rate of 1.80%[83]. - The company has focused on providing integrated solutions in clinical settings, transitioning from single product sales to comprehensive surgical packages across multiple medical departments[46]. Environmental and Social Responsibility - The company has established advanced pollution control facilities and maintains compliance with environmental regulations across all subsidiaries[138]. - The company aims to achieve carbon peak and carbon neutrality targets three and ten years ahead of national goals, respectively[154]. - The company donated nearly 8 million yuan worth of epidemic prevention materials to several universities to support their pandemic response[155]. - A total of over 1.1 million yuan was donated to the China Women's Development Foundation, including 8,000 maternity packages and two health vehicles for women and children in remote areas[155]. Corporate Governance - The financial report has been confirmed as true, accurate, and complete by the company's management[2]. - The company plans not to distribute cash dividends, issue bonus shares, or increase capital from reserves[3]. - The company has not reported any significant changes in advertising and marketing expenses, which totaled ¥235,198,138.16, a slight increase of 0.52%[79]. - The company has not experienced any bankruptcy reorganization or significant litigation matters during the reporting period[157][158].